Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) is among the best fast money stocks to buy now. During the first quarter, Goldman Sachs Group Inc. expanded its holdings in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) by 93.6%. Following the purchase of 358,412 shares, the leading bank now owns 741,329 shares of the company’s stock, translating to an investment of $2,787,000 and an ownership of nearly 1.08%. Oppenheimer is among the many research firms bullish on Olema Pharmaceuticals, Inc. (NASDAQ:OLMA). After the ...

Core Viewpoint - Pfizer has not abandoned vepdegestrant but has deprioritized it, seeking new partners for the project with Arvinas, reflecting the challenges in the innovative drug industry [1][2][4] Group 1: Clinical Trial Results - The VERITAC-2 trial results showed that vepdegestrant achieved one of its dual primary endpoints in ESR1 mutant patients but failed to demonstrate significant improvement in progression-free survival (PFS) in the intent-to-treat population [2][3] - The trial's outcome indicates that vepdegestrant could not meet its core objective of covering the entire patient population, missing out on a significant market opportunity [2][3] Group 2: Market Position and Competition - Vepdegestrant is likely to struggle in a highly competitive market, as it has not differentiated itself from other second-generation SERDs, with Menarini's elacestrant showing superior clinical benefits [3][4] - The decision to seek new partners suggests that both Pfizer and Arvinas are acknowledging the limited competitive edge of vepdegestrant in the current landscape [4][5] Group 3: Company Performance and Market Sentiment - Arvinas has seen its market value plummet from a peak of $8 billion to approximately $552 million, illustrating the volatility and risks associated with innovative drug development [6] - The initial excitement surrounding vepdegestrant's early clinical data has not translated into sustained market success, highlighting the unpredictability of clinical trials [6][7] Group 4: Industry Insights - The situation with vepdegestrant serves as a cautionary tale for the innovative drug sector, emphasizing the gap between early expectations and later clinical realities [1][6] - The broader innovative drug industry is characterized by a pattern of high expectations followed by significant challenges, necessitating a cautious yet optimistic approach [7]

Core Insights - Olema Pharmaceuticals (OLMA) shares have increased by 46.5% in September following a collaboration agreement with Pfizer (PFE) for its lead product candidate, palazestrant [1][6] - The collaboration involves a phase Ib/II study to evaluate the safety and potential combinability of palazestrant with Pfizer's atirmociclib in patients with ER+/HER2- metastatic breast cancer (MBC) [2][6] - Year-to-date, OLMA stock has risen by 37.2%, outperforming the industry growth of 4% [3] Collaboration Details - The phase Ib/II study is expected to enroll approximately 35 patients, with initiation anticipated by the end of 2025 [3] - Pfizer will supply atirmociclib for the study, while Olema will lead the study and retain exclusive global commercial rights to palazestrant [4][6] - This marks Olema's second partnership with Pfizer, the first being established in 2020 [7] Pipeline Development - Olema is also conducting a pivotal phase III OPERA-01 study for palazestrant as a monotherapy in second/third-line ER+/HER2- MBC, with top-line data expected in the second half of 2026 [8] - In partnership with Novartis (NVS), Olema is evaluating palazestrant in combination with Kisqali (ribociclib) in an ongoing phase Ib/II study, with a pivotal phase III OPERA-02 study planned [9][10] - Olema is exploring palazestrant in combination with a PI3Ka inhibitor and an mTOR inhibitor in separate phase I/II studies [11] Additional Investigational Candidates - Olema has a second investigational candidate, OP-3136, currently in a phase I study for advanced solid tumors, with initial results anticipated in 2026 [12][13] - The global market opportunity for OP-3136 in second/third-line ER+/HER2- MBC is estimated at around $5 billion [13]

Core Insights - Pfizer has strengthened its R&D pipeline through mergers and acquisitions (M&A) and successful clinical trials over the past decade [1] - The company expects to have eight or more blockbuster oncology medicines in its portfolio by 2030 [4][10] Oncology Pipeline - Pfizer has advanced its oncology pipeline with several candidates in late-stage development, including vepdegestrant, atirmociclib, and sigvotatug vedotin [2][10] - Sasanlimab is under review for high-risk non-muscle invasive bladder cancer, and Pfizer has exclusive rights to develop SSGJ-707, a dual PD-1 and VEGF inhibitor [3] Recent Approvals and Growth - In 2023, Pfizer achieved a record with nine new medicine/vaccine approvals, and in 2024, it gained approval for a gene therapy for hemophilia [5][10] - New products are contributing to top-line growth, and the company maintains a robust R&D pipeline with potential blockbuster drugs [6] Competitive Landscape - Major competitors in the oncology space include AstraZeneca, Merck, Johnson & Johnson, and Bristol-Myers, each with significant oncology sales contributing to their overall revenues [8][9][11] Financial Performance - Pfizer's stock has declined 1.2% in 2023, while the industry has seen a 1.5% increase [12] - The company's shares are trading at a price/earnings ratio of 8.01, lower than the industry average of 14.75 and its own 5-year mean of 10.71 [13] Earnings Estimates - The Zacks Consensus Estimate for 2025 earnings has increased from $3.05 to $3.13 per share, while the estimate for 2026 remains stable at $3.09 [14]

Group 1 - Pfizer Inc. is considered an undervalued stock with a strong market position and is currently a recommended buy [1] - Olema Pharmaceuticals has entered into a collaboration and supply agreement with Pfizer for the treatment of metastatic breast cancer, focusing on the palazestrant-atirmociclib combination in a clinical trial involving approximately 35 patients, expected to start in H2 2025 [1][2] - Pfizer will supply atirmociclib for the Phase 1b/2 study led by Olema, with the aim of establishing palazestrant as a potential backbone endocrine therapy for metastatic breast cancer [2] Group 2 - Pfizer has shown financial resilience with improved profit margins, expanding cash flows, and a stronger balance sheet, contributing to its stable dividend [2] - The company is actively pursuing new acquisitions and partnerships to support its growth outlook for 2030 [2] - Pfizer is a biopharmaceutical company that has been committed to developing transformative medicines and vaccines since its founding in 1849 [3]

Core Viewpoint - Olema Pharmaceuticals has announced a new clinical trial collaboration with Pfizer to evaluate the combination of palazestrant and atirmociclib in treating metastatic breast cancer, aiming to establish palazestrant as a potential backbone endocrine therapy [1][2] Group 1: Clinical Trial Collaboration - The collaboration involves a Phase 1b/2 study to assess the safety and combinability of palazestrant and atirmociclib in patients with ER+/HER2- metastatic breast cancer [1][2] - Pfizer will supply atirmociclib for the study, while Olema will lead the trial [2] - This marks Olema's second clinical trial agreement with Pfizer, following a previous agreement in November 2020 [3] Group 2: Product and Pipeline Information - Olema's lead product candidate, palazestrant (OP-1250), is an orally available complete estrogen receptor antagonist and selective ER degrader, currently in a Phase 3 trial called OPERA-01 [4][5] - Palazestrant has received FDA Fast Track designation for treating ER+/HER2- metastatic breast cancer that has progressed after endocrine therapy [5] - The company is also developing OP-3136, a KAT6 inhibitor, which is in a Phase 1 clinical study [4] Group 3: Future Plans and Expectations - The new study is expected to involve approximately 35 patients, with initiation anticipated in the second half of 2025 [6] - Successful results from this study could inform a pivotal Phase 3 trial for the combination therapy in the frontline metastatic breast cancer setting [6]

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving Arvinas, Inc. and its officers or directors [1] Company Developments - On May 1, 2025, Arvinas announced the removal of plans for a Phase 3 first-line combination trial with atirmociclib and a Phase 3 second-line combination trial with a CDK4/6 inhibitor from its joint development plan with Pfizer [3] - The decision to remove these trials was based on a review of emerging information, external data results, the evolving treatment landscape in metastatic breast cancer, and long-term capital allocation [3] - Arvinas also announced a workforce reduction of approximately one-third to streamline operations and enable efficient progression of its portfolio, with completion planned for the second quarter of 2025 [3] - Following this news, Arvinas's stock price fell by $2.39 per share, or 24.84%, closing at $7.23 per share on May 1, 2025 [3]

Core Insights - Relay Therapeutics announced updated interim clinical data for RLY-2608, showing a median progression-free survival (PFS) of 11.0 months in second-line patients with PI3Kα-mutated, HR+/HER2- metastatic breast cancer [1][2] - The company plans to initiate a pivotal Phase 3 trial, ReDiscover-2, in mid-2025 [2][16] - RLY-2608 is the first known allosteric, pan-mutant, and isoform-selective inhibitor of PI3Kα, designed to improve tolerability and efficacy compared to standard treatments [11][12] Clinical Data Summary - The updated data indicate a median PFS of 10.3 months overall and 11.0 months for second-line patients, with a clinical benefit rate of 67% [7][8] - Among 64 patients receiving the recommended Phase 3 dose (RP3D) of 600mg BID, 44% had received two or more prior lines of therapy [5][8] - The study enrolled 118 patients with PI3Kα-mutated, HR+, HER2- locally advanced or metastatic breast cancer [4][8] Safety and Tolerability - RLY-2608 + fulvestrant was generally well tolerated, with low-grade treatment-related adverse events (TRAEs) being manageable and reversible [8][15] - Only 36% of patients experienced a Grade 3 TRAE, with no Grade 4-5 TRAEs reported [15] Future Directions - The company is progressing two front-line triplet regimens, one with atirmociclib and another with ribociclib, both currently in dose escalation [9][16] - Continued enrollment in the Phase 1/2 ReInspire study for vascular malformations is also planned [16]

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving Arvinas, Inc. and its officers or directors [1] Group 1: Company Developments - On May 1, 2025, Arvinas announced the removal of plans for a Phase 3 first-line combination trial with atirmociclib and a second-line combination trial with a CDK4/6 inhibitor from its joint development plan with Pfizer [2] - The decision to remove these trials was based on a review of emerging information, external data results, the evolving treatment landscape in metastatic breast cancer, and long-term capital allocation [2] - Arvinas also announced a workforce reduction of approximately one-third to streamline operations and enable efficient progression of its portfolio, with completion planned for the second quarter of 2025 [2] - Following this news, Arvinas's stock price fell by $2.39 per share, or 24.84%, closing at $7.23 per share on May 1, 2025 [2]

Core Insights - Relay Therapeutics has extended its cash runway into 2029, with approximately $710 million in cash, cash equivalents, and investments as of March 31, 2025, which is expected to fund key initiatives including the ReDiscover-2 trial and vascular malformations clinical trial [1][5][6] Financial Performance - Revenue for Q1 2025 was $7.7 million, a decrease from $10.0 million in Q1 2024, primarily due to the completion of performance obligations under an Exclusive License Agreement with Elevar [6] - Research and development expenses decreased to $73.8 million in Q1 2025 from $82.4 million in Q1 2024, attributed to strategic cost reductions [7] - General and administrative expenses also saw a decline, totaling $18.7 million in Q1 2025 compared to $19.8 million in Q1 2024 [8] - The net loss for Q1 2025 was $77.1 million, or $0.46 per share, an improvement from a net loss of $81.4 million, or $0.62 per share, in Q1 2024 [9][14] Strategic Initiatives - The company has implemented strategic cost reductions aimed at fully funding key value drivers, including the completion of the ReDiscover-2 Phase 3 trial and the initiation of the RLY-2608 Phase 1 trial for vascular malformations [2][4] - Specific cost-saving measures included reducing the research run rate spend by approximately 80% and decreasing research-stage programs from four to one [4] - A reduction in workforce by approximately 70 people was executed, alongside a global out-license of RLY-4008 with Elevar Therapeutics, which has potential for downstream economics [4] Clinical Development - The initiation of the Phase 3 ReDiscover-2 trial of RLY-2608 in combination with fulvestrant for advanced breast cancer is on track for mid-2025 [4] - An abstract has been accepted for presentation at ASCO, focusing on updated efficacy data for RLY-2608 in combination with fulvestrant [4] - The Phase 1 trial for vascular malformations was initiated in Q1 2025 [4]